A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Amgen
Masonic Cancer Center, University of Minnesota
Amgen
Allogene Therapeutics
Columbia University
Fondazione Italiana Linfomi - ETS
Peking University People's Hospital
Fred Hutchinson Cancer Center
University of Rochester
Tata Memorial Centre
Peter MacCallum Cancer Centre, Australia
First Affiliated Hospital of Zhejiang University
Ruijin Hospital
Instituto do Cancer do Estado de São Paulo
Hospital Universitario Dr. Jose E. Gonzalez
Munich Leukemia Laboratory
Institute of Hematology & Blood Diseases Hospital, China
PETHEMA Foundation